AstraZeneca PLC

Pharmaceutical industry

FDA Grants Orphan Drug Status to AstraZeneca's MERREM I.V. for Treating Life-threatening Lung Infections in CF Patients

The U.S. Food and Drug Administration (FDA) has granted AstraZeneca orphan drug status for its anti-infective medicine, MERREM I.V. (meropenem for injection), specifically for the management of acute pulmonary exacerbations in Cystic Fibrosis (CF) patients with chronic lower respiratory tract infections. This move enables AstraZeneca to continue researching